Editorial: Genomic strategies for efficient microbial cell factories

Downloaded from: https://research.chalmers.se, 2023-12-14 04:24 UTC

Citation for the original published paper (version of record):

N.B. When citing this work, cite the original published paper.
Editorial: Genomic strategies for efficient microbial cell factories

Eugene Fletcher¹*, Yun Chen², Luis Caspeta³ and Amir Feizi⁴*

¹Escarpment Laboratories, Guelph, ON, Canada, ²Department of Biology and Biological Engineering, Chalmers University of Technology, Göteborg, Sweden, ³Universidad Nacional Autonoma de Mexico, Cuernavaca, Mexico, ⁴OMass Therapeutics, Oxford, United Kingdom

KEYWORDS
yeast, design-build-test-learn (DBTL) cycle, diatoms, synthetic biology, xylanases, direct RNA sequencing, friedelin, biomanufacturing

Following a renewed commitment to build a sustainable bioeconomy, there has been a heightened shift in interest from the production of petroleum based chemicals to biomanufacturing. To make biomanufacturing competitive with chemical synthesis, it is important to develop microbial cell factories that can efficiently utilize cheap and readily available feedstocks. These feedstocks are then metabolized to yield value-added products in high titres that can be easily scaled up to commercial quantities. Advances in synthetic biology have paved the way for efficient microbial design and improvement to reduce the cost and time of feedstock bioprocessing. These cell factories can further be optimized by fine-tuning relevant metabolic pathways utilizing the iterative and systematic Design-Build-Test-Learn (DBTL) cycle (Carbonell et al., 2018). Currently, automation and machine learning technologies are being integrated into the DBTL cycle to increase the throughput, efficiency and turnaround time of developing efficient microbial strains (Carbonell et al., 2018). Also recently, the advent of sequencing and CRISPR/Cas technology enabled the development of a molecular toolbox to edit the genome of microbial hosts as a core principle of strain engineering, and fundamental to the DBTL cycle. In parallel, progress made in developing omics technologies has resulted in lots of data required to build robust genome-scale metabolic models which can be used to predict and optimize metabolic fluxes in microbial cell factories during biomanufacturing. Genome editing technologies have been well-established for a handful of microbial strains including bacteria and yeast (Yang & Blenner 2020; Arroyo-Olarte et al., 2021; Krogerus et al., 2021). Future work will apply these tools to non-conventional microorganisms that are more capable of producing specific value-added compounds.

In this research topic, we highlight a broad range of reviews and original research covering several applications of genomic strategies (Figure 1) being applied to improve complex sugar consumption, and the production of non-native compounds in eukaryotic cell factories.

Transcriptomic data is essential in understanding global gene expression of microbial hosts under different condition (Caspeta et al., 2014; Fletcher et al., 2017). This data can be fed into genome-scale metabolic models and the DBTL cycle to make microbial cell factories...
pathway is engineered in this yeast (Van Maris et al., 2007). To address this challenge, an alternative approach is required to improve the utilization of carbohydrate polymers such as xylans in *S. cerevisiae*. Procopio et al. review the current state of xylan (xylose polymer) metabolism in yeast where the focus is on engineering *S. cerevisiae* to assimilate these polymers to produce bioethanol. Both extracellular utilization through cell surface engineering and intracellular transport followed by polymer degradation have been exploited. In some cases, engineering *S. cerevisiae* to express non-native xylanases from bacteria and other fungi has been reported to result in a non-specific metabolic burden. Hence, complementing rational engineering with adaptive laboratory evolution presents a promising genomic strategy for efficient yeast engineering to convert complex lignocellulosic sugars into bioethanol.

Lastly, expanding the repertoire of high-value compounds produced by microbial cell factories will require exploiting non-conventional microbial hosts in order to tap into the unique biochemistries of their metabolic pathways. In that regard, microalgae such as diatoms offer excellent opportunities that have not been fully explored. Having an innate ability to produce large amounts of lipids (Yi et al., 2017), diatoms serve as perfect hosts for the production of biofuels and bioactive compounds such as carotenoids and fatty acids. The production of non-native compounds with diatoms is, however, limited by lack of genetic tools required to engineer its genome. Chen et al. highlight the potential application of genome engineering tools such as CRISPR in diatoms. Furthermore, the first sequenced genome of a diatom is discussed which has made it possible to build genome-scale metabolic models for diatoms. In order to fast track the development of diatoms as suitable microbial cell factories, future work should go into developing high quality genome annotations essential for building more comprehensive metabolic models in diatoms. In well-studied organisms like *E. coli* and *S. cerevisiae*, genome-scale metabolic models have played a key role in guiding metabolic engineering strategies (Gu et al., 2019). Thus, metabolic engineering of diatom cell factories will benefit from such metabolic models.

We conclude by emphasizing that the articles presented in this research topic provide a glimpse of the role of genome-wide tools in making microbial cell factories more efficient at producing high titres of desired biochemicals. We anticipate that these studies will inspire the development of new genomic tools as well as the improvement of existing tools for microbial strains design and engineering. Ultimately, improved microbial performance will enhance biomanufacturing and fast track the efforts towards creating a sustainable and environmentally-friendly society.

**Author contributions**

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Acknowledgements

We are grateful to all the authors who contributed to this research topic. We would also like to acknowledge the reviewers that provided valuable insights and comments to the manuscripts.

Conflict of interest

EF was employed by the Escarpment Laboratories. AF was employed by OMass Therapeutics.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References


